Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Data Horizon Corporation (3628.T)
Hiroshima, JP
Data Horizon Corporation offers specialized health data support solutions to insurance providers across Japan. The company develops and supplies medical information services, encompassing health-relevant data and notifications about generic drugs, alongside a comprehensive system designed to support health-related businesses. Founded in 1981, its headquarters are situated in Hiroshima, Japan. Data Horizon Corporation operates as a subsidiary of DeNA Co., Ltd.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -11.13% | +25.44% | +16.43% | +18.13% | +3.09% | +14.55% | +16.67% | -76.48% | -60.16% | +30.44% | +305.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Healthcare Information Services: +14.2%+2.6% Q1'26: -2.1% (vs Q1'25)
-
EPS growth Medical - Healthcare Information Services: +43.1%-266.9% Q1'26: +107.4% (vs Q1'25)
-
FCF margin FCF growth · Medical - Healthcare Information Services: +49.2%-36.6% Q1'26: -9.4% (vs Q1'25)
-
EBIT margin Medical - Healthcare Information Services: +8.8%-13.4% Q1'26: +16.1% (vs Q1'25)
-
ROIC Medical - Healthcare Information Services: +5.2%-18.1% Q1'26: +21.1% (vs Q1'25)
-
Share dilution Medical - Healthcare Information Services: -0.1%+0.1% ★ Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Healthcare Information Services: -0.74×58.09× Q1'26: 3.59× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2022 actual |
Mar 2023 actual |
|---|---|---|---|---|---|---|
| Revenue |
1.83B
est: 2.03B (-9.9%)
|
2.54B
est: 2.03B (+25.4%)
|
2.26B
est: 2.50B (-9.7%)
|
2.78B
est: 3.18B (-12.5%)
|
2.99B
est: 4.00B (-25.2%)
|
4.41B
est: 4.00B (+10.3%)
|
| EBITDA |
189.40M
est: -257.03M (+173.7%)
|
394.40M
est: -257.03M (+253.4%)
|
138.48M
est: -316.54M (+143.7%)
|
374.86M
est: -402.64M (+193.1%)
|
-136.32M
est: -506.46M (+73.1%)
|
-1.59M
est: -506.46M (+99.7%)
|
| EBIT |
105.76M
est: -456.81M (+123.2%)
|
290.04M
est: -456.81M (+163.5%)
|
36.57M
est: -562.58M (+106.5%)
|
263.12M
est: -715.60M (+136.8%)
|
-315.91M
est: -900.12M (+64.9%)
|
-498.50M
est: -900.12M (+44.6%)
|
| Net Income |
101.97M
est: 120.50M (-15.4%)
|
210.60M
est: 120.50M (+74.8%)
|
21.31M
est: 156.86M (-86.4%)
|
201.76M
est: 241.43M (-16.4%)
|
-410.80M
est: 286.67M (-243.3%)
|
-664.86M
est: 286.67M (-331.9%)
|
| SGA |
762.80M
est: 742.53M (+2.7%)
|
939.77M
est: 742.53M (+26.6%)
|
967.78M
est: 914.45M (+5.8%)
|
1.11B
est: 1.16B (-4.3%)
|
1.32B
est: 1.46B (-9.9%)
|
1.02B
est: 1.46B (-30.3%)
|
| EPS |
9.71
est: 9.50 (+2.2%)
|
19.99
est: 9.50 (+110.4%)
|
2.01
est: 12.37 (-83.7%)
|
19.00
est: 19.03 (-0.2%)
|
-38.68
est: 22.60 (-271.2%)
|
-53.33
est: 22.60 (-336.0%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Shinichiro Naito | Managing Executive Officer & General Manager of Administration Division | — | male |
| Sho Segawa | Chief Executive Officer, President & Director | — | — |
| Yoshiyuki Towata | Managing Executive Officer & Director | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 3628.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
